Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow

NCT ID: NCT06106997

Last Updated: 2023-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-31

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is:

* Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this clinical study is to investigate the clinical feasibility of a deep learning-based MRI-only workflow for brain radiotherapy, that eliminates the registration uncertainty through calculation of a synthetic CT (sCT) from MRI data.

A total of 54 patients with an indication for radiation treatment of the brain and stereotactic mask immobilization will be recruited. All study patients will receive standard therapy and imaging including both CT and MRI. All patients will receive dedicated RT-MRI scans in treatment position. An sCT will be reconstructed from an acquired MRI DIXON-sequence using a commercially available deep learning solution on which subsequent radiotherapy planning will be performed. Through multiple quality assurance (QA) measures and reviews during the course of the study, the feasibility of an MRI-only workflow and comparative parameters between sCT and standard CT workflow will be investigated holistically. These QA measures include feasibility and quality of image guidance (IGRT) at the linear accelerator using sCT derived digitally reconstructed radiographs in addition to potential dosimetric deviations between the CT and sCT plan. The aim of this clinical study is to establish a brain MRI-only workflow as well as to identify risks and QA mechanisms to ensure a safe integration of deep learning-based sCT into radiotherapy planning and delivery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Tumor, Primary Brain Tumor - Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sCT workflow

sCT workflow

Group Type OTHER

brain radiotherapy

Intervention Type RADIATION

brain radiotherapy planned on synthetic CTs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

brain radiotherapy

brain radiotherapy planned on synthetic CTs

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Patient older than 18 years
* Tumor or metastases in the brain
* Immobilization with stereotactic mask
* Treatment on stereotactic linear accelerator (2.5 mm leafs) equipped with 2D/2D X-ray system

Exclusion Criteria

* Metal in the body, metal implants, pacemakers or other patient-specific factors that are a contraindication to an MRI scan
* Metal implants, pacemakers or other patient-specific factors associated with increased risk from an MRI scan
* Renal insufficiency (eGFR \< 60 ml/min), allergy or other patient-specific factors that constitute a contraindication to contrast administration
* Renal insufficiency (eGFR \< 60 ml/min), allergy or other patient-specific factors associated with an increased risk from contrast administration
* Patients who are institutionalized in care facilities, prisons or other supervised facilities.
* Patients under guardianship
* Non-consenting patients
* Pregnant or breastfeeding patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Bert, Prof. Dr. rer. nat

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Erlangen, Strahlenklinik

Florian Putz, PD Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Erlangen, Strahlenklinik

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Erlangen, Universitätsklinikum Strahlenklinik

Erlangen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christoph Bert, Prof. Dr. rer. nat

Role: CONTACT

++49(0)9131-85-44213

Florian Putz, PD Dr. med.

Role: CONTACT

++49(0)9131-85-33405

References

Explore related publications, articles, or registry entries linked to this study.

Grigo J, Szkitsak J, Hofler D, Fietkau R, Putz F, Bert C. "sCT-Feasibility" - a feasibility study for deep learning-based MRI-only brain radiotherapy. Radiat Oncol. 2024 Mar 8;19(1):33. doi: 10.1186/s13014-024-02428-3.

Reference Type DERIVED
PMID: 38459584 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

sCT-Feasibility

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.